{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-080576","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2023-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.943958+00:00","generated_at":"2026-06-13T08:35:12.826211+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eloxx reports ELX-02 Phase 2 data: partial remission in 1 of 3 Alport patients","bullets":["Patient 4401-02 showed ~49% average reduction in UPCR (p=0.009) after 8 weeks of ELX-02.","Two other patients (4401-01, 4402-01) had no meaningful change in proteinuria.","All three patients had COL4A4 nonsense mutations and background RAAS blockade.","Patient 4401-02's remission rebounded 1 month after treatment withdrawal.","Results from KOL Day on June 27, 2023 disclosed via 8-K filed July 13."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-080576","json":"https://secwatch.observer/filing/0001104659-23-080576.json","markdown":"https://secwatch.observer/filing/0001104659-23-080576.md","text":"https://secwatch.observer/filing/0001104659-23-080576.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923080576/0001104659-23-080576-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923080576/tm2321215d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:35:12.826211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}